Literature DB >> 3436337

Erythromycin lactobionate: pharmacokinetics and uterine tissue levels.

A Segui1, D Milon, M Cormier, G Lepesant.   

Abstract

Erythromycin is well-known for its properties of tissular diffusion. An estimation of its concentration in uterine tissue seemed worthwhile, in order to justify the use of erythromycin lactobionate in uterine infections by sensitive micro-organisms. The authors studied the uterine levels of this macrolid, after perfusion of 1g of erythromycin lactobionate, over a period of one hour. The protocol involved a group of 15 women, who were to undergo a hysterectomy for benign non-inflammatory pathology. The uterine specimens and plasmatic pharmacokinetics of the antibiotic constitute the data. The concentrations of antibiotic were determined by microbiological methods. 2 sets of results emerge: during perfusion, the uterine erythromycin levels are equal or inferior to simultaneous serum levels. after perfusion, the uterine levels are superior to serum levels. A bicompartmental linear model was used, which simulated the tissular levels in standard treatment with erythromycin lactobionate. If the erythromycin 4 micrograms/ml critical concentration is compared with uterine tissue concentration, the antibiotic may be expected to be active against a uterine affected by sensitive micro-organisms during a period of approximately 5 hours. This result must be confirmed by a clinical study.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436337     DOI: 10.1007/BF03189891

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  4 in total

Review 1.  A review of the applications of physiologically based pharmacokinetic modeling.

Authors:  K J Himmelstein; R J Lutz
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

2.  Concept of a volume of distribution and possible errors in evaluation of this parameter.

Authors:  S Riegelman; J Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

3.  Penetration of methicillin, oxacillin, and cephalothin into bone and synovial tissues.

Authors:  R H Fitzgerald; P J Kelly; R J Snyder; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

4.  Pharmacokinetics of intravenous erythromycin.

Authors:  P G Welling; W A Craig
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

  4 in total
  2 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.